ECDC reviewed the response plan and the 2019 update strives to further support EU Member States to develop and implement national strategies and interventions to control the threat of multidrug-resistant and extensively drug-resistant gonorrhoea in a multidisciplinary approach by outlining the suggested public health response to this threat with several vital components.
External quality assessment (EQA) is an essential part of any laboratory-based surveillance system, allowing for the monitoring of performance and comparability of results from participating laboratories, identification of potential issues, and deployment of resources and training where necessary.
This report presents a comprehensive analysis of the results of a 2017 survey among men who have sex with men (MSM). Based on the responses of some 128 000 participants in Europe, it provides insights on their knowledge of HIV, viral hepatitis and sexually transmitted infections (STI), sexual behaviour, prevention needs and testing habits.
In April 2019, Finland reported false-negative or equivocal results in patients tested for Chlamydia trachomatis (CT) using Aptima Combo 2 Assay (Hologic) (AC2).
A pilot project was carried out to investigate the feasibility of HIVDR surveillance in EU/EEA countries and to make recommendations for the design and implementation of a potential future HIVDR surveillance system at the European level.
ECDC comment on the study 'Detection in the United Kingdom of the Neisseria gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018' by Eyre et al. in the Eurosurveillance edition of 7 March 2019.